• Explore /
  • Poster
  • / Final overall survival from a phase 3 trial of <i>nab</i>-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.

Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.

Abstract Poster

Authors

null

Evan Hersh

University of Arizona Cancer Center, Tucson, AZ

Evan Hersh , Michele Del Vecchio , Michael Paul Brown , Richard Kefford , Carmen Loquai , Alessandro Testori , Shailender Bhatia , Ralf Gutzmer , Andrew Mark Haydon , Caroline Robert , Mingyu Li , Ileana Elias , Markus Frederic Renschler , Axel Hauschild

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT00864253

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 9045)

DOI

10.1200/jco.2014.32.15_suppl.9045

Abstract #

9045

Poster Bd #

249

Abstract Disclosures

Similar Posters

First Author: Evan Hersh

First Author: Rahima Jamal

First Author: Caroline Robert

First Author: Reinhard Dummer